---
title: "CSPC PHARMA  Expects Interim Consolidated Profit of Approximately RMB5.9B-6.2B"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293910986.md"
description: "CSPC PHARMAexpects consolidated profit attributable to owners for the six months ended June 30, 2026, to range from RMB5.9 billion to RMB6.2 billion. This represents a significant increase from RMB2.55 billion in the same period last year, driven by substantial growth in licensing fee income and steady revenue expansion in its finished drug business."
datetime: "2026-07-27T09:44:23.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293910986.md)
  - [en](https://longbridge.com/en/news/293910986.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293910986.md)
generator: "portal-rs"
---

# CSPC PHARMA  Expects Interim Consolidated Profit of Approximately RMB5.9B-6.2B

CSPC PHARMA (01093.HK) -0.250 (-2.924%) Short selling $222.79M; Ratio 33.954% expects the group's consolidated profit attributable to owners of the company for the six months ended 30 June 2026 to range from approximately RMB5.9 billion to RMB6.2 billion, representing a significant increase from RMB2.55 billion in the same period last year, mainly due to a substantial increase in licensing fee income compared with the same period last year and steady growth in revenue from the finished drug business. (ha/u)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-07-27 16:25.)  

AASTOCKS Financial News

### Related Stocks

- [01093.HK](https://longbridge.com/en/quote/01093.HK.md)
- [300765.CN](https://longbridge.com/en/quote/300765.CN.md)

## Related News & Research

- [CSPC Pharma FY26 H1 profit attributable to shareholders more than doubled to RMB 6.09 billion; revenue rises 40.1% to RMB 18.59 billion](https://longbridge.com/en/news/296433558.md)
- [CSPC PHARMA  1H26 Net Profit Surges Nearly 1.4x, Interim DPS Up 28.6% to HKD0.18](https://longbridge.com/en/news/296435690.md)
- [M Stanley Raises CSPC PHARMA  TP to HKD12, Rating Overweight](https://longbridge.com/en/news/296557755.md)
- [CSPC PHARMA  Shares Rise 15% as Phase Ib/II Clinical Trial of SYS 6090 Injection for Hepatocellular Carcinoma Launches at First Center in China](https://longbridge.com/en/news/296423040.md)
- [Weekly Recap: US$30M AstraZeneca upfront and SYS6063 Phase I start](https://longbridge.com/en/news/296034254.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**